ARTICLE | Company News
Cornerstone Therapeutics sales and marketing update
November 25, 2013 8:00 AM UTC
Cornerstone launched Bethkis tobramycin inhalation solution in the U.S. to manage Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). The wholesale acquisition cost for a 28-day ...